South Africa Allergy Therapeutics Market Analysis

South Africa Allergy Therapeutics Market Executive Summary

South Africa Allergy Therapeutics Market was valued at $151 Mn in 2022 and is estimated to reach $272 Mn in 2030, exhibiting a CAGR of 7.63% during the forecast period.

Allergens are substances found in the environment that can occasionally cause allergic reactions in the body. Common allergies comprise items such as dust mites, pollen, and mildew, as well as specific foods like milk, eggs, soy, and almonds. Allergies can cause a wide range of symptoms, from minor ones like a runny nose and itchy eyes to serious ones like anaphylaxis, which is marked by unconsciousness and breathing problems. Medications such as antihistamines and nasal corticosteroids can be prescribed, while immunotherapy and allergen avoidance techniques are viable forms of treatment.

There is a significant difference between what is considered to be a food allergy and what is clinically diagnosed. Up to 34% of people think they or a family member has a food allergy, and 22% avoid particular foods just because they might contain an allergen. But only 1% to 6% of people genuinely tests positive for allergies. Urban children have a 2.5% frequency of food allergies, with the most prevalent allergens being raw egg white (1.9%), cooked egg (0.8%), peanut (0.8%), cow's milk (0.1%), and fish (0.1%). While the frequency of food allergies generally is 9.0%, 11.4% of people report being sensitized to any food in an urban setting.

The safety and efficacy of sublingual immunotherapy (SLIT) for the treatment of grass pollen allergy in children is being investigated in a South African trial. SLIT is a non-invasive therapy technique that involves gradually desensitizing the immune system by applying allergens under the tongue.

The South African Health Products Regulatory Authority (SAHPRA) has approved Glenmark's Ryaltris nasal spray, which is intended to treat seasonal allergic rhinitis. This clearance offers a new treatment option for South African patients who experience allergic rhinitis during particular seasons.

Market Dynamics

Market Growth Drivers

Demand for Advanced Therapies: People are actively looking for simple and effective ways to manage a variety of allergies, including biologics, sublingual immunotherapy (SLIT), and nasal sprays. Positive opportunities for long-term, sustainable solutions are presented by the rise of personalized medicine and ongoing advances in drug development.

Urbanization and Changing Lifestyles: The trend toward an increase in the need for allergy treatment pharmaceuticals is mostly being driven by urbanization and changes in lifestyle, such as greater exposure to indoor allergens such dust mites and outdoor pollutants.

Rising Incidence of Allergies: Allergies impact a huge percentage of the population, especially those with respiratory diseases like asthma and allergic rhinitis. These diseases may be becoming more common due to factors including dust mites, changing dietary patterns, and environmental pollutants.

Market Restraints

Regulatory Challenges: Navigating the regulatory landscape for the importation and registration of innovative allergy medicines is a challenging and time-consuming task for pharmaceutical companies. This complexity can prevent the market from growing as it impedes the timely introduction of fresh therapeutic alternatives.

High Cost of Treatment: Treatments for allergies can be quite expensive for certain patients, particularly if they involve Allergen Immunotherapy methods such as immunotherapy injections and SLIT tablets. Allergy drugs high cost may prohibit people from using and accessing them broadly, which would restrict their market penetration.

Access and Equity: The distribution of advanced diagnostic equipment and specialized allergists between rural and urban locations is clearly different, with urban concentrations receiving a greater share of these resources and rural people having less access to appropriate diagnosis and treatment. Furthermore, a lack of knowledge regarding allergy symptoms and accessible treatments may lead to missed opportunities for early intervention and delayed diagnoses, particularly in underprivileged populations.

Healthcare Policies and Regulatory Landscape

The South African Health Products Regulatory Authority (SAHPRA) is the primary regulatory body overseeing drug regulations and healthcare policies in the country. SAHPRA is in charge of overseeing the nation's pharmaceutical, medical device, and other health product industries with regard to efficacy, safety, and quality. Within the parameters set forth by the Medicines and Related Substances Act of 1965, the authority functions. Pharmaceutical businesses must adhere to the strict regulatory standards established by SAHPRA in order to market or introduce new products. This entails providing thorough paperwork, which includes data from clinical trials, to prove the medications' safety and effectiveness.

Competitive Landscape

Key Players

• GlaxoSmithKline
• Sanofi
• Novartis
• AstraZeneca
• Bayer
• Aspen Pharmacare
• Adcock Ingram
• Lupin Ltd.
• Cipla Medpro
• Pfizer